JP2013531070A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531070A5
JP2013531070A5 JP2013520827A JP2013520827A JP2013531070A5 JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5 JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5
Authority
JP
Japan
Prior art keywords
oxadiazol
benzyl
ethyl
acid
azetidinecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013520827A
Other languages
English (en)
Japanese (ja)
Other versions
JP5788507B2 (ja
JP2013531070A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044597 external-priority patent/WO2012012477A1/en
Publication of JP2013531070A publication Critical patent/JP2013531070A/ja
Publication of JP2013531070A5 publication Critical patent/JP2013531070A5/ja
Application granted granted Critical
Publication of JP5788507B2 publication Critical patent/JP5788507B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013520827A 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物 Expired - Fee Related JP5788507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36592310P 2010-07-20 2010-07-20
US61/365,923 2010-07-20
PCT/US2011/044597 WO2012012477A1 (en) 2010-07-20 2011-07-20 Substituted 3-phenyl-1,2,4-oxadiazole compounds

Publications (3)

Publication Number Publication Date
JP2013531070A JP2013531070A (ja) 2013-08-01
JP2013531070A5 true JP2013531070A5 (enExample) 2015-07-23
JP5788507B2 JP5788507B2 (ja) 2015-09-30

Family

ID=44628993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520827A Expired - Fee Related JP5788507B2 (ja) 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物

Country Status (6)

Country Link
US (1) US8822510B2 (enExample)
EP (1) EP2595969B1 (enExample)
JP (1) JP5788507B2 (enExample)
CN (1) CN103124727B (enExample)
ES (1) ES2539256T3 (enExample)
WO (1) WO2012012477A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
AU2013286860B2 (en) 2012-07-02 2017-10-26 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US8859598B2 (en) * 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8957051B2 (en) 2012-10-04 2015-02-17 Allergan, Inc. Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
WO2015073140A1 (en) * 2013-11-14 2015-05-21 Allergan, Inc. 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
WO2015108577A1 (en) * 2014-01-15 2015-07-23 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
SI3373931T1 (sl) * 2015-11-13 2023-02-28 Oppilan Pharma Ltd. Heterociklične spojine za zdravljenje bolezni
WO2019101511A1 (en) * 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
CN115197186B (zh) * 2021-04-12 2024-04-16 中科催化新技术(大连)股份有限公司 一种生物质基吡喃糖苷衍生物的制备方法
CN115197282B (zh) * 2021-04-12 2024-10-11 中科催化新技术(大连)股份有限公司 一种吡喃糖苷衍生物的制备方法
CN116375671A (zh) * 2021-12-24 2023-07-04 晶美晟光电材料(南京)有限公司 一种包含四氢吡喃结构的液晶化合物的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1-磷酸(内皮分化基因)受体激动剂的(3,4-二取代)丙酸酯
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CN1950349A (zh) 2004-05-04 2007-04-18 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的1,2,4-噁二唑衍生物
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
EP1873153B1 (en) 2005-04-22 2010-07-07 Daiichi Sankyo Company, Limited 3-azetidinecarboxylic acid derivatives for use as immunosuppressants
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
TWI382984B (zh) 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
CN101562977A (zh) * 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
CA2700917A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
WO2010033701A2 (en) * 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
EP2370438A1 (en) * 2008-12-04 2011-10-05 Exelixis, Inc. Imidazo [1,2a]pyridine derivatives, their use as s1p1 agonists and methods for their production
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases

Similar Documents

Publication Publication Date Title
JP2013531070A5 (enExample)
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2019038820A5 (enExample)
JP2012528178A5 (enExample)
JP2017511794A5 (enExample)
JP2005536475A5 (enExample)
JP2011502958A5 (enExample)
JP2016538313A5 (enExample)
JP2019537605A5 (enExample)
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
JP2004502670A5 (enExample)
JP2016517406A5 (enExample)
JP2014526500A5 (enExample)
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2014530900A5 (enExample)
JP2007519649A5 (enExample)
JP2014513110A5 (enExample)
JP2019510799A5 (enExample)
JP2010523682A5 (enExample)
JP2011509309A5 (enExample)
JP2019537603A5 (enExample)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2010508338A5 (enExample)
JP2018502906A5 (enExample)
JP2014523851A5 (enExample)